Compare ClearPoint Neuro Inc (CLPT) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Nasdaq Inc — how do they compare? ClearPoint Neuro Inc trades at $16.04 (market cap $478.63M), while Nasdaq Inc trades at $90.28 (market cap $49.77B). The key difference: Nasdaq Inc is far larger — about 104× ClearPoint Neuro Inc's market cap, and Nasdaq Inc pays a 1.27% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | NDAQ | |
|---|---|---|
Market Cap | $478.63M | $49.77B |
Sector | Health | Financials |
52-Week High | $29.60 | $100.98 |
52-Week Low | $8.66 | $76.85 |
Enterprise Value | $506.63M | $56.84B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Nasdaq (NDAQ) trades at $89.21, up 1.28% with a bullish technical signal and strong earnings momentum, beating estimates for three consecutive quarters. The company reported robust 2025 revenue of $8.26 billion and net income of $1.79 billion, with a net margin of 23.03%. Recent news highlights include SK Hynix's Nasdaq debut and positive analyst coverage, with 61% of analysts rating it a buy.
Outlook remains positive given earnings consistency and a $105.60 consensus price target, but risks include high valuation multiples and debt levels. Cash flow volatility from investing and financing activities warrants monitoring, though operational strength supports growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
